Company Overview of BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. The company offers the Helix biotherapeutic delivery system product line that offers a catheter system for the local delivery of cells, gene, and protein therapeutics to the heart; and the Morph vascular access product line, which offers catheter products for interventional medicine. Its lead therapeutic candidate is the CardiAMP Cell Therapy System that is in Phase III pivotal trial for ischemic systolic heart failure. The CardiAMP Cell Therapy System comprises cell potency screening test, a point of care cell processing platform, and a biotherapeutic delivery system. BioCardi...
125 Shoreway Road
San Carlos, CA 94070
Founded in 2002
Key Executives for BioCardia, Inc.
Chief Executive Officer, President and Director
Vice President of Operations
Director of Research and Development
Vice President of Regulatory
Compensation as of Fiscal Year 2015.
BioCardia, Inc. Key Developments
BioCardia, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 01:30 PM
Oct 2 15
BioCardia, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 01:30 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Peter A. Altman, Chief Executive Officer, President and Director.
BioCardia Seeks Acquisitions
Jun 16 15
BioCardia, Inc. has filed an IPO in the amount of $57.50 million. BioCardia said, "We also may use a portion of the net proceeds to acquire complementary businesses, products, services or technologies. The amount and timing of these expenditures will vary depending on a number of factors, including competitive and technological developments and the rate of growth, if any, of our business."
BioCardia, Inc. Auditor Raises 'Going Concern' Doubt
Jun 16 15
BioCardia, Inc. filed its Annual on Jun 16, 2015 for the period ending Dec 31, 2014. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|